142 related articles for article (PubMed ID: 18559974)
1. Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation.
Marx PF; Brondijk TH; Plug T; Romijn RA; Hemrika W; Meijers JC; Huizinga EG
Blood; 2008 Oct; 112(7):2803-9. PubMed ID: 18559974
[TBL] [Abstract][Full Text] [Related]
2. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.
Foley JH; Kim P; Nesheim ME
J Biol Chem; 2008 Apr; 283(14):8863-7. PubMed ID: 18252711
[TBL] [Abstract][Full Text] [Related]
3. Increased zymogen activity of thrombin-activatable fibrinolysis inhibitor prolongs clot lysis.
Mishra N; Buelens K; Theyskens S; Compernolle G; Gils A; Declerck PJ
J Thromb Haemost; 2012 Jun; 10(6):1091-9. PubMed ID: 22498006
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability.
Ceresa E; De Maeyer M; Jonckheer A; Peeters M; Engelborghs Y; Declerck PJ; Gils A
J Thromb Haemost; 2007 Oct; 5(10):2105-12. PubMed ID: 17666015
[TBL] [Abstract][Full Text] [Related]
5. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties.
Boffa MB; Wang W; Bajzar L; Nesheim ME
J Biol Chem; 1998 Jan; 273(4):2127-35. PubMed ID: 9442053
[TBL] [Abstract][Full Text] [Related]
6. Role of isoleucine residues 182 and 183 in thrombin-activatable fibrinolysis inhibitor.
Marx PF; Havik SR; Bouma BN; Meijers JC
J Thromb Haemost; 2005 Jun; 3(6):1293-300. PubMed ID: 15946220
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage.
Marx PF; Hackeng TM; Dawson PE; Griffin JH; Meijers JC; Bouma BN
J Biol Chem; 2000 Apr; 275(17):12410-5. PubMed ID: 10777524
[TBL] [Abstract][Full Text] [Related]
8. Insights into the molecular inactivation mechanism of human activated thrombin-activatable fibrinolysis inhibitor.
Sanglas L; Arolas JL; Valnickova Z; Aviles FX; Enghild JJ; Gomis-Rüth FX
J Thromb Haemost; 2010 May; 8(5):1056-65. PubMed ID: 20088943
[TBL] [Abstract][Full Text] [Related]
9. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
Zhou X; Weeks SD; Ameloot P; Callewaert N; Strelkov SV; Declerck PJ
J Thromb Haemost; 2016 Aug; 14(8):1629-38. PubMed ID: 27279497
[TBL] [Abstract][Full Text] [Related]
10. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability.
Walker JB; Bajzar L
J Biol Chem; 2004 Jul; 279(27):27896-904. PubMed ID: 15128744
[TBL] [Abstract][Full Text] [Related]
11. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant.
Ceresa E; Van de Borne K; Peeters M; Lijnen HR; Declerck PJ; Gils A
J Biol Chem; 2006 Jun; 281(23):15878-83. PubMed ID: 16595693
[TBL] [Abstract][Full Text] [Related]
12. Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation.
Zhou X; Declerck PJ
J Thromb Haemost; 2015 Jun; 13(6):1084-9. PubMed ID: 25773535
[TBL] [Abstract][Full Text] [Related]
13. The crystal structure of thrombin-activable fibrinolysis inhibitor (TAFI) provides the structural basis for its intrinsic activity and the short half-life of TAFIa.
Anand K; Pallares I; Valnickova Z; Christensen T; Vendrell J; Wendt KU; Schreuder HA; Enghild JJ; Avilés FX
J Biol Chem; 2008 Oct; 283(43):29416-23. PubMed ID: 18669641
[TBL] [Abstract][Full Text] [Related]
14. Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor.
Marx PF; Havik SR; Marquart JA; Bouma BN; Meijers JC
J Biol Chem; 2004 Feb; 279(8):6620-8. PubMed ID: 14660622
[TBL] [Abstract][Full Text] [Related]
15. Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides.
Plug T; Marquart JA; Marx PF; Meijers JC
J Thromb Haemost; 2015 Nov; 13(11):2093-101. PubMed ID: 26341360
[TBL] [Abstract][Full Text] [Related]
16. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis.
Schneider M; Nesheim M
J Thromb Haemost; 2003 Jan; 1(1):147-54. PubMed ID: 12871552
[TBL] [Abstract][Full Text] [Related]
17. Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis.
Sanglas L; Valnickova Z; Arolas JL; Pallarés I; Guevara T; Solà M; Kristensen T; Enghild JJ; Aviles FX; Gomis-Rüth FX
Mol Cell; 2008 Aug; 31(4):598-606. PubMed ID: 18722183
[TBL] [Abstract][Full Text] [Related]
18. The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex.
Wu C; Kim PY; Manuel R; Seto M; Whitlow M; Nagashima M; Morser J; Gils A; Declerck P; Nesheim ME
J Biol Chem; 2009 Mar; 284(11):7059-67. PubMed ID: 19074424
[TBL] [Abstract][Full Text] [Related]
19. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme.
Schneider M; Boffa M; Stewart R; Rahman M; Koschinsky M; Nesheim M
J Biol Chem; 2002 Jan; 277(2):1021-30. PubMed ID: 11684677
[TBL] [Abstract][Full Text] [Related]
20. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor.
Boffa MB; Bell R; Stevens WK; Nesheim ME
J Biol Chem; 2000 Apr; 275(17):12868-78. PubMed ID: 10777585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
